When was Atsena Therapeutics founded?

Atsena Therapeutics was founded in 2020 and raised its 1st funding round within a year of its incorporation.

Where is Atsena Therapeutics located?

Atsena Therapeutics is headquartered in Durham, United States.

How many employees does Atsena Therapeutics have?

As of Sep 30, 2026, the latest employee count at Atsena Therapeutics is 53.

Is Atsena Therapeutics a funded company?

Atsena Therapeutics is a funded company, having raised a total of $238M across 5 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Apr 2020.

When was the latest funding round of Atsena Therapeutics?

Atsena Therapeutics' latest funding was a $***** Grant (prize money) round on Sep 11, 2025, with participation from 1 investor.

Where does Atsena Therapeutics rank among its competitors?

Atsena Therapeutics ranks 19th amongst 136 active competitors, of which 47 are funded. It stands 5th in terms of total funding among its competitors. The most recent competitor to raise funding was Epicrispr Bio, which secured $177M in May, 2026.

Who are the top competitors of Atsena Therapeutics?

Atsena Therapeutics' top competitors include 4D Molecular Therapeutics, Regenxbio and CureVac. Among them, Epicrispr Bio secured the most recent funding round in May, 2026.

Atsena Therapeutics - 2026 Company Profile, Team, Funding & Competitors

Atsena Therapeutics is a series C company based in Durham (United States), founded in 2020 by Shannon Boye. It operates as a Developer of gene therapies for the treatment of ocular diseases. Atsena Therapeutics has raised $238M in funding from investors like Sofinnova Investments, Hatteras Venture Partners and Bain Capital Life Sciences. The company has 136 active competitors, including 47 funded and 27 that have exited. Its top competitors include companies like 4D Molecular Therapeutics, Regenxbio and CureVac.

Company Details

Developer of gene therapies for the treatment of ocular diseases. It leverages AAV.SPR, a novel spreading capsid, to evaluate best-in-class gene therapy candidate, ATSN-201, for X-linked retinoschisis a rare pediatric disease.

Website: atsenatx.com
Email ID: *****@atsenatx.com

Key Metrics

Founded Year

2020

Location

Durham, United States

Stage

Series C

Total Funding

$238M in 5 rounds

Latest Funding Round

Grant (prize money), Sep 11, 2025, $*****

Investors

Sofinnova Investments & 11 more

Ranked

19^th among 136 active competitors

Employee Count

53 as on Sep 30, 2026

Similar Companies

4D Molecular Therapeutics & 142 more

View Atsena Therapeutics' full profile

Atsena Therapeutics is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
ATSENA THERAPEUTICS CIN: 845181493 , United States, Active	Dec 31, 1999	-	20 (As on Dec 31, 2024)	-
ATSENA THERAPEUTICS, INC. CIN: 84-5181493 , United States, Active	Oct 28, 2019	-	23 (As on Dec 31, 2021)	-

Atsena Therapeutics has raised a total funding of $238M over 5 rounds. Its first funding round was on Apr 2020. Its latest funding round was a Grant (prize money) round on Sep 11, 2025 for $*****. 1 investor participated in its latest round. Atsena Therapeutics has 12 institutional investors.

Here is the list of recent funding rounds of Atsena Therapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 11, 2025	7726407	Grant (prize money)	3764835	9336771	1021822	1208720
Mar 27, 2025	6037621	Series C	8315843	5376310	9180333	Wellington & 4 more
Oct 02, 2023	3220089	Series B	5616737	5784325	5401810	6164306

Access funding benchmarks and valuations. Sign up today!

View details of Atsena Therapeutics's funding rounds and investors

The founders of Atsena Therapeutics is Shannon Boye.

Here are the details of Atsena Therapeutics' key team members:

Shannon Boye: Founder & Director of Atsena Therapeutics.

View details of Atsena Therapeutics's Founder profiles and Board Members

Atsena Therapeutics' employee count trend

Atsena Therapeutics has 53 employees as of Sep 26. Here is Atsena Therapeutics's employee count trend over the years:

Employee count trend for Atsena Therapeutics

Uncover Atsena Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Atsena Therapeutics include 4D Molecular Therapeutics, Regenxbio and CureVac. Here is the list of Top 10 competitors of Atsena Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	4D Molecular Therapeutics 2013, Emeryville (United States), Public	Developer of gene therapeutics for genetic disorders	$187M	Viking Global Investors, BVF Partners & 18 others	67/100
2nd	Regenxbio 2008, Rockville (United States), Public	Developer of AAV Gene Therapy for rare genetic diseases	$108M	Brookside Capital, Venrock & 15 others	67/100
3rd	CureVac 2000, Tubingen (Germany), Acquired	Developer of mRNA-based therapeutics against cancer and infectious diseases	$975M	Dievini, Gates & 16 others	67/100
4th	Rezolute 2012, Denver (United States), Public	Developing transformative therapies for rare diseases, focusing on hyperinsulinism (HI)	-	BVF Partners, Lincoln Park Capital & 8 others	64/100
5th	Kriya Therapeutics 2012, Redwood City (United States), Series D	Developer of therapeutic solutions for the treatment of diabetes	$938M	Patient Square Capital, Foresite Capital ... & 16 others	63/100
6th	AAVantgarde Bio 2021, Milano (Italy), Series B	Developer of gene therapies using Adeno-Associated Viral vectors	$206M	Atlas Venture, Forbion & 11 others	63/100
7th	Aviceda Therapeutics 2018, Cambridge (United States), Series C	Developer of biotherapeutics for glycol-immune diseases	$255M	Omega Funds, Marshall Wace & 10 others	62/100
8th	Kala Pharmaceuticals 2009, Waltham (United States), Public	Developer of ophthalmic treatments based on its mucosal penetrating product platform	$115M	Polaris Partners, Lux Capital & 17 others	62/100
9th	Epicrispr Bio 2018, San Francisco (United States), Series C	Developer of therapeutics for multiple disease	$245M	Octagon Capital Advisors, Ally Bridge Group ... & 10 others	62/100
10th	MeiraGTx 2015, New York City (United States), Public	Developer of gene therapies for ocular and neurodegenerative diseases	-	Perceptive Advisors, ATW Partners & 6 others	61/100
19th	Atsena Therapeutics 2020, Durham (United States), Series C	Developer of gene therapies for the treatment of ocular diseases	$238M	Bain Capital Life Sciences, Abingworth & 10 others	58/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Atsena Therapeutics's competitors? Click here to see the top ones

Atsena Therapeutics has made no investments or acquisitions yet.

Here is the latest report on Atsena Therapeutics's sector:

Free

Ophthalmology - Sector Report

Edition: September, 2026 (68 Pages)

View all reports related to Atsena Therapeutics

Media has covered Atsena Therapeutics for a total of 4 events in the last 1 year, 3 of them have been about company updates and 1 about people movement.